ADC Therapeutics shares surge 14.18% after-hours on positive LOTIS-5/7 trial updates and stronger cash position.

ADC Therapeutics surged 14.18% in after-hours trading following the release of its Q4 2025 and full-year financial results, alongside key clinical updates. The company reported reduced net losses, a $261.3 million cash runway into 2028, and strong efficacy data from the LOTIS-7 trial (90% best overall response rate). Management highlighted near-term catalysts, including LOTIS-5 topline data in Q2 2026 and potential regulatory approvals, while an amended financing agreement with HealthCare Royalty improved strategic flexibility. These developments, coupled with a 50% reduction in operating costs and positive investor sentiment from institutional buying, drove the sharp post-earnings rally.